Healthcare M&A
Written by Sarah Mitchell
A potential acquisition of Revolution Medicines would deepen AbbVie’s oncology push and mark one of the largest biotech deals in years.
AbbVie is in “advanced” talks to buy Revolution Medicines, a cancer-focused biotechnology company, in a deal that could be worth more than $20 billion, according to a Wall Street Journal report citing people familiar with the matter.
The report landed quickly in markets. Revolution Medicines shares jumped about 30% and triggered multiple volatility halts, while AbbVie’s stock rose roughly 5% on the day. Revolution was valued at more than $16 billion as of Wednesday afternoon in the run-up to the move.
Reuters separately reported that AbbVie is in advanced talks, also citing the Wall Street Journal’s account. Reuters noted the report did not include a firm deal value, and that Revolution had a market value of more than $15.4 billion at the stock’s last close. Factoring in a typical takeover premium, the Journal said Revolution could be valued at about $20 billion or more.
If a transaction is finalized, it would stand out as one of the biggest healthcare deals in recent years and would add to a growing list of acquisitions AbbVie has pursued to support longer-term growth. Reuters reported AbbVie has spent more than $20 billion on acquisitions since 2023 as it looks to offset pressure after its flagship rheumatoid arthritis treatment Humira lost patent protection.
The talks are not a done deal. The Wall Street Journal said an agreement could come together soon if negotiations avoid last-minute snags. AbbVie and Revolution Medicines did not immediately respond to requests for comment in the Reuters report.
For AbbVie, the strategic appeal is clear: oncology remains a high-priority growth area across big pharma, and late-stage or differentiated cancer assets can command premium valuations. Revolution Medicines has built its profile around targeted cancer medicines, with investor attention increasingly drawn to its experimental programs aimed at hard-to-treat tumors.
One program specifically cited in the reports is daraxonrasib, an experimental drug being developed by Revolution Medicines. Bloomberg Intelligence research referenced in the coverage suggested the pancreatic cancer market could expand nearly tenfold to more than $3 billion by 2035, with daraxonrasib described as a potential leader among experimental approaches in that space.
The stock reaction reflects how sharply investors can reprice a biotech when a potential acquirer steps in. A premium takeover offer can instantly change the risk profile for shareholders, particularly for companies whose value is closely tied to the outcome of clinical trials and the pace of regulatory looks. For the buyer, the calculus is different: paying up can be justified if an asset can expand a pipeline, open a new therapeutic franchise, or improve the odds of replacing revenues that face erosion as older products lose exclusivity.
For now, the only confirmed detail is that discussions are advanced, not finalized. Markets will watch for any formal announcement, details on valuation and structure, and how AbbVie frames the fit of Revolution’s portfolio within its longer-term oncology strategy.
Learn more: AbbVie | Revolution Medicines
